MannKind Corporation (MNKD) Covered Calls

MannKind Corporation is a biopharmaceutical company focused on transforming the lives of people with cardiometabolic and orphan lung diseases. Leveraging its proprietary Technosphere® dry-powder delivery platform, the company develops and commercializes inhaled therapies that provide rapid action and needle-free alternatives. As of early 2026, MannKind is experiencing a catalyst-rich year driven by the expansion of its endocrine and orphan lung franchises.

You can sell covered calls on MannKind Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MNKD (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

MannKind Corporation (MNKD) operates through two primary therapeutic pillars: Endocrine and Orphan Lung. Its flagship product, Afrezza (insulin human) Inhalation Powder, remains the only FDA-approved inhaled ultra-rapid-acting mealtime insulin. In 2026, Afrezza is entering a new growth phase following the January 2026 label update for dose conversion and the highly anticipated May 29, 2026, PDUFA date for its pediatric application (ages 4–17).

The company’s Orphan Lung business is anchored by Tyvaso DPI (treprostinil), which is manufactured for and commercialized by United Therapeutics. This partnership provides MannKind with a steady stream of high-margin royalties. Additionally, MannKind has expanded its cardiometabolic footprint with the 2025 acquisition of Furoscix, a subcutaneous diuretic for heart failure. A major catalyst for July 2026 is the FDA decision on the ReadyFlow Autoinjector, which would allow Furoscix to be delivered in under 10 seconds.

Competitive Landscape

The biopharmaceutical sector for chronic disease is intensely competitive. MannKind differentiates itself through its drug-device combination expertise and the clinical superiority of its Technosphere delivery system, which mimics natural physiological insulin spikes more closely than traditional injectables. In the options market, MNKD is a favorite for volatility traders due to its frequent regulatory milestones.

1. United Therapeutics Corporation: MannKind’s primary partner and a competitor in the pulmonary hypertension space; the most direct benchmark for Tyvaso DPI performance.
2. Insmed Incorporated: A key peer in the orphan lung disease market, specifically focusing on inhaled therapies for rare respiratory conditions.
3. Vertex Pharmaceuticals Incorporated: A major biotechnology peer that serves as an industry standard for high-growth orphan disease portfolios.
4. Insulet Corporation: A competitor in the diabetes management space, providing wearable insulin delivery solutions.
5. Tandem Diabetes Care, Inc.: A peer in the endocrine technology market known for its insulin pump systems and high option liquidity.

Strategic Outlook and Innovation

MannKind’s 2026 strategic outlook is defined by "Revenue Diversification." The company is moving toward an annual revenue run rate of over $450 million, supported by the growing adoption of Afrezza and the full integration of Furoscix. Innovation centers on the MNKD-201 (Nintedanib DPI) program for idiopathic pulmonary fibrosis (IPF); topline data from the INFLO-1 Phase 1b study is expected in the second half of 2026. This program represents a potential "blockbuster" opportunity by providing a better-tolerated, inhaled version of the current standard-of-care backbone treatment.

The company recently fortified its balance sheet by settling the remaining $36 million of its 2.5% convertible notes in March 2026, significantly reducing its debt load. With two major FDA decisions scheduled for mid-2026 (Afrezza pediatric and Furoscix autoinjector), MannKind is positioned to transition from a single-product company into a diversified leader in cardiometabolic and pulmonary medicine. Management continues to leverage the Technosphere platform to explore new dry-powder formulations for high-unmet-need diseases.

Want more examples? MNDY Covered Calls | MNOV Covered Calls